Have a feature idea you'd love to see implemented?
Let us know!
ARMP Armata Pharmaceuticals Inc
Price (delayed)
$2.1
Market cap
$75.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$193.69M
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is
Highlights
The revenue is up by 47% since the previous quarter and by 35% year-on-year
ARMP's gross profit is up by 47% since the previous quarter and by 35% year-on-year
The company's debt rose by 23% YoY but it fell by 4% QoQ
The company's quick ratio has shrunk by 88% YoY and by 22% QoQ
The equity has contracted by 11% from the previous quarter
Key stats
What are the main financial stats of ARMP
Market
Valuations
Earnings
Shares outstanding
36.18M
Market cap
$75.98M
Enterprise value
$193.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
13.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.43
Revenue
$5.47M
EBIT
-$32.45M
EBITDA
-$31.21M
Free cash flow
-$42.08M
Per share
Balance sheet
Liquidity
EPS
-$1.14
Free cash flow per share
-$1.16
Book value per share
-$1.41
Revenue per share
$0.15
TBVPS
$2.62
Total assets
$98.24M
Total liabilities
$149.21M
Debt
$140.33M
Equity
-$50.97M
Working capital
-$95.82M
Debt to equity
-2.75
Current ratio
0.19
Quick ratio
0.21
Net debt/EBITDA
-3.77
Margins
Efficiency
Dividend
EBITDA margin
-571%
Gross margin
100%
Net margin
-756.6%
Operating margin
-758.7%
Return on assets
-38.9%
Return on equity
N/A
Return on invested capital
-25.9%
Return on capital employed
N/A
Return on sales
-593.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARMP stock price
How has the Armata Pharmaceuticals stock price performed over time
Intraday
0.48%
1 week
-21.64%
1 month
-10.99%
1 year
-1.41%
YTD
-35.19%
QTD
-11.39%
Financial performance
How have Armata Pharmaceuticals's revenue and profit performed over time
Revenue
$5.47M
Gross profit
$5.47M
Operating income
-$41.48M
Net income
-$41.36M
Gross margin
100%
Net margin
-756.6%
The company's net margin has surged by 58% QoQ and by 48% YoY
The revenue is up by 47% since the previous quarter and by 35% year-on-year
ARMP's gross profit is up by 47% since the previous quarter and by 35% year-on-year
The company's net income rose by 38% QoQ and by 30% YoY
Growth
What is Armata Pharmaceuticals's growth rate over time
Valuation
What is Armata Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
13.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.43
Armata Pharmaceuticals's EPS has increased by 38% QoQ and by 31% YoY
The equity has contracted by 11% from the previous quarter
ARMP's price to sales (P/S) is 92% lower than its 5-year quarterly average of 163.4 and 45% lower than its last 4 quarters average of 25.1
The revenue is up by 47% since the previous quarter and by 35% year-on-year
Efficiency
How efficient is Armata Pharmaceuticals business performance
Armata Pharmaceuticals's return on sales has surged by 63% QoQ and by 59% YoY
ARMP's return on invested capital is up by 49% year-on-year and by 37% since the previous quarter
Armata Pharmaceuticals's ROA has increased by 36% from the previous quarter and by 32% YoY
Dividends
What is ARMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARMP.
Financial health
How did Armata Pharmaceuticals financials performed over time
ARMP's total assets is 34% lower than its total liabilities
ARMP's current ratio has dropped by 89% year-on-year and by 24% since the previous quarter
The company's quick ratio has shrunk by 88% YoY and by 22% QoQ
ARMP's debt to equity has soared by 70% year-on-year and by 13% since the previous quarter
The company's debt rose by 23% YoY but it fell by 4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.